New Delhi: The Russian Direct Funding Fund (RDIF) and Dr Reddy’s Laboratories Restricted, a world pharmaceutical firm headquartered in India, have agreed to cooperate on scientific trials and distribution of Sputnik V Covid-19 vaccine in India, Russia’s sovereign wealth fund revealed in an announcement on Wednesday.
Sputnik V, an adenovirus vector-based vaccine, was developed by the Gamaleya Scientific Analysis Institute of Epidemiology and Microbiology, together with the Russian Direct Funding Fund and registered on August 11.
“On regulatory approval in India, RDIF shall supply to Dr Reddy’s 100 million doses of the vaccine. The Sputnik V vaccine, which is based on well-studied human adenoviral vector platform with proven safety, is undergoing clinical trials for the coronavirus pandemic,” stated an announcement from the fund.
The Russian Direct Funding Fund stated that the deliveries may probably start in late 2020 topic to completion of profitable trials and registration of the vaccine by regulatory authorities in India.
“The agreement between RDIF and Dr Reddy’s reflects the growing awareness of countries and organisations to have a diversified anti-COVID vaccine portfolio to protect their populations,” RDIF added.
Earlier this month, NITI Aayog member, Dr V.Ok. Paul, had stated that the Russian authorities has sought India’s assist in manufacturing the Sputnik V vaccine and likewise to conduct Part-Three trials or bridging research within the nation.
Addressing a press convention on Tuesday, ICMR Director Common Balram Bhargava additionally stated, “Russia has a good history of vaccine manufacturing hence we assume that this vaccine is also good. There is a dialogue going on between the high-level committees of the governments of India and Russia. We are trying to work out its mechanism.”